

PROINSULIN INTACT ELISA.



UNLOCK THE FUTURE OF DIABETES DETECTION: PROINSULIN INTACT ELISA FOR EARLY AND ACCURATE DIAGNOSIS.

PRODUCT

RE53061

Proinsulin Intact ELISA

Proinsulin, primarily produced in pancreatic β -cells, undergoes processing into insulin and C-peptide. While typically found in low concentrations in plasma of healthy individuals, insulin resistance (IR) or hyperglycemia prompts increased insulin secretion, leading to a disruption in secretion patterns. Consequently, plasma levels of intact proinsulin rise while insulin levels drop, serving as a specific biomarker for β -cell dysfunction and IR, also independently correlating with cardiovascular disease risk.

In clinical practice, fasting morning intact proinsulin emerges as a highly specific indicator of relevant insulin resistance and β -cell dysfunction, causative of type 2 diabetes. It can be used in guiding insulin resistance therapy selection and monitoring therapeutic efficacy on β -cell function. Elevated fasting intact proinsulin levels signify insulin resistance and potential prediabetes, urging proactive treatment to mitigate cardiovascular risks.

During the oral glucose tolerance test, 2-hour intact proinsulin levels emerge as a robust predictor of future type 2 diabetes development, often preceding detectable glucose, HbA1c, and insulin changes by up to 4 years. Elevated fasting intact proinsulin levels may also signal conditions like insulinoma or precede type 1 diabetes manifestation.^{1,2}




Figure 1: Intact versus total proinsulin.

- Total proinsulin = Intact proinsulin plus cleavage fragments (des32,33)
- Cleavage products are stable for hours, can be up to 30-50% of total proinsulin
- Exclude any possible reason for cleavage products (e.g. intake of fat food hours before blood collection)
- Intact proinsulin allows a better functional assessment of the β -cell activity / dynamic

Transform diabetes detection with Proinsulin Intact ELISA.

- **Early detection:** Intact proinsulin indicates type 2 prediabetes before glucose changes. It predicts type 2 diabetes up to 4 years before clinical diagnosis.
- **Insight into insulin resistance:** Elevated intact proinsulin levels offer valuable information on insulin resistance, contributing to a comprehensive understanding of metabolic health.

- **Diagnostic accuracy:** The ELISA kit distinguishes itself by measuring intact proinsulin with high specificity, avoiding potential confounding factors present in total proinsulin assays.
- **Clinical utility:** Widely employed in reputable research and clinical studies^{3,4}, Proinsulin Intact ELISA is recognized for its clinical relevance and reliability.

Intact proinsulin indicates **type 2 prediabetes** before glucose changes are detectable.

It can predict type 2 diabetes (T2D) development up to 4 years before clinical diagnosis. Glucose, insulin and HbA1c cannot detect prediabetes and predict later T2D development.




Figure 2: Glucose, insulin and intact proinsulin profiles in oral glucose tolerance test (OGTT) for patients who developed T2D within 4 years from this test. Results are compared to healthy persons who did not develop T2D.

- Only intact proinsulin predicts later T2D development.⁵
- Glucose in mg/dl; insulin in μU/ml; intact proinsulin in pmol/l.

Choose Proinsulin Intact ELISA (RE53061)* for:

- **Trusted results:** Calibrated with the latest WHO Standard 09/296.⁶
- **Precision matters:** Proven performance in external ring trial (published by INSTAND).
- **Ease of use:** Test can be performed within 3 hours.

*Distributed by IBL International GmbH, Part of Tecan Group.

References

1. Pfützner, A., Hermanns, I., Ramljak, S., Demircik, F., Pfützner, A. H., Kann, P. H., & Weber, M. M. (2015). Elevated intact proinsulin levels during an oral glucose challenge indicate progressive β -cell dysfunction and may be predictive for development of type 2 diabetes. *Journal of Diabetes Science and Technology*, 9(6), 1307-1312.
2. Vangipurapu, J., Stančáková, A., Kuulasmaa, T., Kuusisto, J., & Laakso, M. (2015). Both fasting and glucose-stimulated proinsulin levels predict hyperglycemia and incident type 2 diabetes: a population-based study of 9,396 Finnish men. *PLoS One*, 10(4), e0124028.
3. Sims, E. K., Geyer, S. M., Long, S. A., & Herold, K. C. (2023). High proinsulin: C-peptide ratio identifies individuals with stage 2 type 1 diabetes at high risk for progression to clinical diagnosis and responses to teplizumab treatment. *Diabetologia*, 1-9.
4. Sims, E. K., Bundy, B. N., Stier, K., Serti, E., Lim, N., Long, S. A., ... & Type 1 Diabetes TrialNet Study Group. (2021). Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. *Science translational medicine*, 13(583), eabc8980.
5. Pfützner A, Sachenheimer D, Lier A. Erhöhtes intaktes Proinsulin als früher Hinweis auf einen zukünftigen Typ-2-Diabetes. *Diabetes, Stoffwechsel und Herz* Band 27, Feb 2018
6. WHO Expert Committee on Biological Standardization, & World Health Organization. (2014). WHO international collaborative study of the proposed 1st international standard for human proinsulin (No. WHO/BS/2014.2237). World Health Organization.

Distributed by

IBL International GmbH
Flughafenstrasse 52a
22335 Hamburg
Germany

Phone: +49 (0)40-53 28 91-0
Fax: +49 (0)40-53 28 91-11
Email: IBL@Tecan.com
www.tecan.com/immunoassays

LEARN MORE



.....
Australia +61 3 9647 4100 **Austria** +43 62 46 89 330 **Belgium** +32 15 42 13 19 **China** +86 21 220 63 206 **France** +33 4 72 76 04 80 **Germany** +49 79 51 94 170
Italy +39 02 92 44 790 **Japan** +81 44 556 73 11 **Netherlands** +31 18 34 48 17 4 **Nordic** +46 8 750 39 40 **Singapore** +65 644 41 886 **Spain** +34 93 595 25 31
Switzerland +41 44 922 89 22 **UK** +44 118 9300 300 **USA** +1 919 361 5200 **Other countries** +41 44 922 81 11
.....

Tecan Group Ltd. makes every effort to include accurate and up-to-date information within this publication, however, it is possible that omissions or errors might have occurred. Tecan Group Ltd. cannot, therefore, make any representations or warranties, expressed or implied, as to the accuracy or completeness of the information provided in this publication. Changes in this publication can be made at any time without notice. All mentioned trademarks are protected by law. In general, the trademarks and designs referenced herein are trademarks, or registered trademarks, of Tecan Group Ltd., Männedorf, Switzerland. A complete list may be found at <http://www.tecan.com/trademarks>. Product names and company names that are not contained in the list but are noted herein may be the trademarks of their respective owners. For technical details and detailed procedures of the specifications provided in this document please contact your Tecan representative.

403171 VO.1

Tecan is in major countries a registered trademark of Tecan Group Ltd., Männedorf, Switzerland.

© 2024 Tecan Trading AG, Switzerland, all rights reserved.

www.tecan.com



Please check regulatory status in your country.

Not for in vitro diagnostic use in Australia unless first included in the Australian Register of Therapeutic Goods.

Distributed by Abacus dx

1800 ABACUS (AUS) 0800 222 170 (NZ) | info@abacusdx.com | www.abacusdx.com

